Senicapoc treatment in COVID-19 patients with severe respiratory insufficiency-A randomized, open-label, phase II trial.
Granfeldt A, Andersen LW, Vallentin MF, Hilberg O, Hasselstrøm JB, Sørensen LK, Mogensen S, Christensen S, Grejs AM, Rasmussen BS, Kristiansen KT, Strøm T, Johansen IS, Schjørring OL, Simonsen U.
Granfeldt A, et al.
Acta Anaesthesiol Scand. 2022 Aug;66(7):838-846. doi: 10.1111/aas.14072. Epub 2022 May 13.
Acta Anaesthesiol Scand. 2022.
PMID: 35403225
Free PMC article.
Clinical Trial.
The median senicapoc concentration at 72 h was 62.1 ng/ml (IQR 46.7-71.2). The primary outcome, PaO(2) /FiO(2) ratio at 72 h, was significantly lower in the senicapoc group (mean 19.5 kPa, SD 6.6) than in the control group (mean 24.4 kPa, SD 9.2) (mean difference -5 …
The median senicapoc concentration at 72 h was 62.1 ng/ml (IQR 46.7-71.2). The primary outcome, PaO(2) /FiO(2) ratio at 72 h, was sig …